Larson Votes for Bipartisan Prescription Drug Price Bill in Committee
Washington, D.C. – Today, the Ways and Means Committee marked-up the H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act, which will require more transparency regarding prescription drug prices. Rep. John B. Larson (CT-01) voted to report the bill favorably out of committee. The Ways and Means Committee reported this bipartisan bill unanimously.
“Shining a light on the drug pricing system represents the first step to lowering drug prices for all Americans. Without adequate information, Congress cannot do its job to protect the American people from the exorbitant drug prices we have seen the last few years. The drug pricing system has operated in a cloak of secrecy for too long.,” said Larson. “One of my constituents who works as a sanitation worker in the Hartford area has been prescribed Xarelto, a high-cost clot-busting drug for which there are no generics available. He is unable to afford this medication. Last week he developed a life threatening clot, which this medication could have prevented, and had to be hospitalized.
“No one should have to go through what my constituent went through and have their health be affected because they can’t afford the medicine they need. This legislation is the first step forward in addressing the crisis of the cost prescription drugs in America. I’m proud that we were able to work bipartisanly on this solution, and I look forward to its passage on the House floor.”